[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 361,246
  • Shares Outstanding, K 94,320
  • Annual Sales, $ 35,110 K
  • Annual Income, $ -79,200 K
  • EBIT $ -98 M
  • EBITDA $ -96 M
  • 60-Month Beta 0.34
  • Price/Sales 10.77
  • Price/Cash Flow N/A
  • Price/Book 2.22

Options Overview Details

View History
  • Implied Volatility 250.09% (-187.43%)
  • Historical Volatility 50.49%
  • IV Percentile 81%
  • IV Rank 0.00%
  • IV High 744.42% on 05/18/26
  • IV Low 250.09% on 06/04/26
  • Expected Move (DTE 12) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 130
  • Open Int (30-Day) 118
  • Expected Range 3.83 to 3.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 2
  • High Estimate $-0.18
  • Low Estimate $-0.20
  • Prior Year $-3.47
  • Growth Rate Est. (year over year) +94.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.56 +7.58%
on 05/19/26
4.60 -16.74%
on 05/11/26
-0.37 (-8.81%)
since 05/05/26
3-Month
3.53 +8.50%
on 03/16/26
4.83 -20.70%
on 03/10/26
+0.13 (+3.51%)
since 03/05/26
52-Week
1.35 +183.70%
on 08/11/25
4.83 -20.70%
on 03/10/26
+0.13 (+3.51%)
since 06/05/25

Most Recent Stories

More News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May...

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will...

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals: Q1 Earnings Snapshot

X4 Pharmaceuticals: Q1 Earnings Snapshot

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized...

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

- European Commercialization will be Led by X4 Pharmaceuticals’ Partner, Norgine -  - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON,...

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on...

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals: Q4 Earnings Snapshot

X4 Pharmaceuticals: Q4 Earnings Snapshot

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor...

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management...

XFOR : 3.83 (-4.49%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on...

XFOR : 3.83 (-4.49%)

Business Summary

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 4.24
2nd Resistance Point 4.13
1st Resistance Point 3.98
Last Price 3.83
1st Support Level 3.72
2nd Support Level 3.61
3rd Support Level 3.46

See More

52-Week High 4.83
Last Price 3.83
Fibonacci 61.8% 3.50
Fibonacci 50% 3.09
Fibonacci 38.2% 2.68
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.